These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 22965962)
1. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202 [TBL] [Abstract][Full Text] [Related]
3. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961 [TBL] [Abstract][Full Text] [Related]
4. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M; Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877 [TBL] [Abstract][Full Text] [Related]
5. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334 [TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
7. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509 [TBL] [Abstract][Full Text] [Related]
9. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Belani CP; Fossella F Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485 [TBL] [Abstract][Full Text] [Related]
10. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922 [TBL] [Abstract][Full Text] [Related]
11. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147 [TBL] [Abstract][Full Text] [Related]
12. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099 [TBL] [Abstract][Full Text] [Related]
13. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ; J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323 [TBL] [Abstract][Full Text] [Related]
14. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054 [TBL] [Abstract][Full Text] [Related]
15. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633 [TBL] [Abstract][Full Text] [Related]
16. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283 [TBL] [Abstract][Full Text] [Related]
17. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M Clin Lung Cancer; 2012 Nov; 13(6):505-9. PubMed ID: 22853980 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S; Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639 [TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]